SuperworthCelularity EPS CELU
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$1.70
- Latest quarter, Q2 FY26
- $0.02
- Fiscal year 2025
- −$3.60
Celularity's earnings per share was −$1.70 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.02.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.60 | n/a |
| FY2024 | −$2.66 | n/a |
| FY2023 | −$11.32 | −3873% |
| FY2022 | $0.30 | n/a |
| FY2021 | −$57.20 | n/a |
| FY2020 | −$28.80 | n/a |
| FY2019 | −$0.20 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.02 | n/a | −$1.70 | |
| Q1 FY26 | $0.02 | n/a | −$2.74 | |
| Q4 FY25 | −$0.86 | n/a | −$3.60 | |
| Q3 FY25 | −$0.88 | n/a | −$3.34 | |
| Q2 FY25 | −$1.02 | n/a | −$3.19 | |
| Q1 FY25 | −$0.84 | n/a | −$2.47 | |
| Q4 FY24 | −$0.60 | −220% | −$2.66 | |
| Q3 FY24 | −$0.73 | n/a | −$1.56 | |
| Q2 FY24 | −$0.30 | n/a | −$5.81 | |
| Q1 FY24 | −$1.03 | n/a | −$8.23 | |
| Q4 FY23 | $0.50 | −69% | −$11.32 | |
| Q3 FY23 | −$4.98 | −1760% | −$10.22 |
Against its peers
Companies in Drug Manufacturers - General nearest Celularity's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CELUCelularity | −$1.70 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Celularity
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.